Balancing Internal Focus Against External Capabilities

In pharmaceutical science, several divergent paths typically exhibit clear validity. Decisions often boil down to embracing instead of eschewing risk, to accelerate as the only priority, or to trust a partner rather than emphasize self-reliance. Each molecule, each company or research group possessing that molecule, has an assortment of strengths and weakness to guard against or to leverage. Multiple factors weigh in the balance when deciding how best to move forward, and increasingly the route chosen is to outsource research, development, and manufacturing.

The global contract development and manufacturing organization (CDMO) industry, averaging across several market research firm estimates, is currently valued around $100 billion (1). In part, this growth is shaped through direct regulatory influences suggesting, if not demanding, that a drug have multiple sites of manufacture to spread the risk for supply chain planning. Above regulations, companies also seek to reduce the complexity of their operations internally, and to reallocate internal resources most effectively.

Read this article in BioPharm International's Partnerships for Outsourcing eBook.

About the author

Chris Spivey is editorial director of BioPharm International.

Article details

BioPharm International
eBook: Partnerships for Outsourcing
May 2022
Pages: 18–23

Citation

When referring to this article, please cite it as C. Spivey, “Balancing Internal Focus Against External Capabilities,” BioPharm International Partnerships for Outsourcing eBook (May 2022).